CB1 and CB2 receptors are coupled to the GPCR (G-Protein Coupled Receptor) family of proteins . CB1 is the prominent subtype located within the CNS (Central Nervous System) and are as well expressed within the PNS (Peripheral Nervous System) below in figure is the receptors. The discovery of the CB1 and its prominence within the CNS and PNS has garnered attention for possible treatment of neurodegenerative and neuropsychological disorders that can be treated through this avenue . Although acitvation of CB1 receptors are also indicated with the psychotropic effects negatively assocated with use of psychoactive cannabinoids . The CB2 receptor plays an integrative role within the brain, G.I (Gastro-Intestinal), PNS (Peripheral Nervous System), and the immune system . Unlike the CB1 receptors, the activation of the CB2 Receptors with cannabinoids, do not provide the psychotropic "high" that is associated with agonists of the CB1 receptor, which would be the more likely place to design compounds for better treatment . CB2 plays a significant role in anti-inflammation and remediation in cancer growth . CB2 receptors are implicated in a variety of modulatory functions, including immune suppression, induction of apoptosis, and induction of cell migration [23a]. The CB1 receptors like the CB2 receptors can be allosterically modulated by synthetic ligands, in a positive and negative fashion . THCV is shown to act as an antagonist of the CB1 receptor in small concentrations but can act as a partial agonist at larger concentrations . HHC in animal models are known to bind to the CB1 receptor producing similar effects to THC .